A study in healthy men to test how BI 474121 is tolerated
Phase 1
- Conditions
- Alzheimer disease and Cognitive impairment associated with schizophrenia
- Registration Number
- JPRN-jRCT2071210040
- Lead Sponsor
- Takada Kumiko
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Male
- Target Recruitment
- 32
Inclusion Criteria
Healthy male subjects according to the assessment of the investigator, as based on a
complete medical history including a physical examination, vital signs (blood
pressure[BP], PR) including body temperature, 12-lead ECG, and clinical laboratory tests
at screening visit
Exclusion Criteria
Any finding in the medical examination (including BP, PR or ECG) deviating from normal and assessed as clinically relevant by the investigator at screening visit
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage of subjects with drug-related adverse events
- Secondary Outcome Measures
Name Time Method AUC0and Cmax of BI 474121